Pharma BD Deal Intelligence
Nimbus's $496M AMPK pact with Lilly is paying off: a 2025 research milestone cracked a selectivity problem, and by January 2026 the two signed a larger $1.3B oral-obesity collaboration built directly on it.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly and Company and Nimbus Therapeutics today announced a research collaboration and exclusive worldwide license agreement to develop and commercialize…
Lilly's deal with Nimbus Therapeutics is a $496 million bet on AMP-activated protein kinase activation, a metabolic mechanism that has produced more pipeline…
Nimbus and Lilly announced a new research collaboration and exclusive worldwide license for a novel oral obesity treatment, with Nimbus eligible for…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Nimbus Therapeutics entered a research collaboration and exclusive worldwide license with Eli Lilly to develop and commercialize selective AMPK isoform activators for metabolic diseases. Total deal payments could reach up to $496M plus tiered mid-single to low-double-digit royalties on net sales. Nimbus leads research; Lilly leads development and commercialization. Post-deal development: on February 25, 2025 Nimbus announced it had achieved a research milestone in the collaboration with the discovery of a highly selective isoform-specific AMPK activator, described as solving a decades-old AMPK selectivity challenge (preclinical). The collaboration remained active; in January 2026 Lilly and Nimbus signed a separate, larger ($1.3B potential) oral-obesity collaboration that explicitly built on this 2022 AMPK pact.
37.3M US cases/yr · $80.0B Global type 2 diabetes therapeutics market (2022) · ~41.9% U.S. adult obesity prevalence
Type 2 diabetes affects approximately 37.3 million Americans and prediabetes affects another 96 million, representing one of the largest pharmaceutical markets globally. Obesity, the upstream driver, affects 41.9% of U.S. adults. The therapeutic class hierarchy has been reshaped by GLP-1 receptor agonists (Ozempic/Wegovy, Mounjaro/Zepbound) which deliver substantial weight loss alongside glycemic control, opening a $100B+ projected obesity drug market by 2030. Despite GLP-1 dominance, mechanistic gaps remain: GLP-1 non-responders, GI tolerability dropouts (~20% discontinuation), incomplete metabolic remission in fatty liver/NASH, and the need for orals to expand access beyond injectables. AMP-activated protein kinase (AMPK) is a central energy-sensing kinase regulating glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and hepatic gluconeogenesis. Selective AMPK activator development has historically been frustrated by isoform-specific tissue distribution and on-target liver/cardiac toxicity in pan-activators (e.g., metformin acts indirectly via AMPK). Nimbus's computational chemistry platform enables isoform-selective AMPK activator design (e.g., β1-selective for liver/skeletal muscle), positioning the program as a non-incretin, oral, mechanism-differentiated entry into a GLP-1-saturated landscape.
Type 2 diabetes therapeutics are dominated by incretin-axis MOAs that have absorbed the bulk of pharmaceutical economics over the past five years. GLP-1 receptor agonists are led by Ozempic/Rybelsus/Wegovy (semaglutide, Novo Nordisk) and Mounjaro/Zepbound (tirzepatide GLP-1/GIP dual agonist, Eli Lilly), with Trulicity (dulaglutide, Lilly) as the prior-generation weekly and Victoza (liraglutide, Novo) as the daily legacy. SGLT2 inhibitors include Jardiance (empagliflozin, BI/Lilly), Farxiga (dapagliflozin, AstraZeneca), and Invokana (canagliflozin, J&J). DPP-4 inhibitors (Januvia/Janumet, Merck) and metformin (generic, indirect AMPK activator) form the foundational T2D backbone. Pipeline AMPK activators have been a graveyard. PXL770 (Poxel, β1-selective, Phase 2b NASH discontinued), MK-8722 (Merck, pan-AMPK, halted for cardiac hypertrophy), and academic AICAR analogs all failed translation. Nimbus's bet is that computational structure-based design enables β2-skeletal muscle or β1-hepatic isoform selectivity sufficient to separate efficacy from cardiac risk. Adjacent metabolic programs at Lilly include retatrutide (GLP-1/GIP/glucagon triple agonist, Phase 3) and orforglipron (oral non-peptide GLP-1, Phase 3). The Nimbus AMPK collaboration is a long-cycle, mechanism-differentiated bolt-on rather than a near-term commercial play.
Nimbus announced a research milestone under the 2022 AMPK collaboration: discovery of a highly selective isoform-specific AMPK activator for cardiometabolic diseases (preclinical). Confirms the deal remained active. Nimbus eligible for up to $496M in milestones plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Nimbus Therapeutics LLC (this deal) | 2022 | $496M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2022 deals · Eli Lilly and Company deals · Metabolic deals